Filtered By:
Source: American Heart Journal
This page shows you your search results in order of relevance. This is page number 13.
Order by Relevance | Date
Total 491 results found since Jan 2013.
Prognosis in relation to high-sensitivity cardiac troponin T levels in patients with myocardial infarction and non-obstructive coronary arteries
Conclusions Hs-cTnT levels in MINOCA patients are strong and independent predictors of adverse outcome. Consideration of hs-cTnT levels is important for risk assessment of MINOCA patients.
Source: American Heart Journal - March 11, 2018 Category: Cardiology Source Type: research
Incidence, Timing, and Type of First and Recurrent Ischemic Events in Patients with and without Peripheral Artery Disease after an Acute Coronary Syndrome
Conclusions Patients with PAD have a significantly higher risk of first and recurrent ischemic events in the post-ACS setting. These findings highlight the opportunity for improved treatments in patients with PAD who experience an ACS.
Source: American Heart Journal - March 28, 2018 Category: Cardiology Source Type: research
Design and Rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) Trial
Conclusion CAMELLIA-TIMI 61 is investigating the safety and efficacy of lorcaserin for major adverse cardiovascular events and conversion to diabetes in overweight or obese patients with established cardiovascular disease or multiple cardiovascular risk factors.
Source: American Heart Journal - March 30, 2018 Category: Cardiology Source Type: research
Randomized placebo controlled trial evaluating the safety and efficacy of single low dose intracoronary insulin like growth factor following percutaneous coronary intervention in acute myocardial infarction (RESUS-AMI)
Conclusion In this pilot trial, low dose IGF1, given after optimal mechanical reperfusion in STEMI, is safe but does not improve LVEF. However, there is a signal for a dose dependent benefit on post MI remodeling that may warrant further study.
Source: American Heart Journal - April 3, 2018 Category: Cardiology Source Type: research
An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial
Publication date: June 2018 Source:American Heart Journal, Volume 200 Author(s): Renato D. Lopes, Amit N. Vora, Danny Liaw, Christopher B. Granger, Harald Darius, Shaun G. Goodman, Roxana Mehran, Stephan Windecker, John H. Alexander Background The optimal antithrombotic strategy for patients with atrial fibrillation (AF) who develop acute coronary syndrome (ACS) and/or the need for percutaneous coronary intervention (PCI) is uncertain. The risk of bleeding is a major concern when oral anticoagulation is required to prevent stroke, and concomitant therapy with antiplatelet agents is required to minimize recurrent ischemic ...
Source: American Heart Journal - April 6, 2018 Category: Cardiology Source Type: research
GlycA and hsCRP are Independent and Additive Predictors of Future Cardiovascular Events Among Patients Undergoing Angiography: The Intermountain Heart Collaborative Study
Conclusion In this study, levels of GlycA and hsCRP were independent and additive markers of risk for MACE, death and HF hospitalization.
Source: American Heart Journal - April 6, 2018 Category: Cardiology Source Type: research
Revival of Transcatheter PFO Closure: A meta-analysis of randomized controlled trials
Conclusion According to our meta-analysis TPC plus antiplatelets was superior in terms of stroke prevention when compared to Med-Tx. Furthermore, patients with moderate to severe shunts and those younger than 45years of age were found to benefit most from TPC.
Source: American Heart Journal - April 7, 2018 Category: Cardiology Source Type: research
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE) –TIMI 58 Trial
Conclusion The DECLARE–TIMI 58 trial is testing the hypotheses that dapagliflozin is safe (does not increase) and may reduce the occurrence of major CV events. DECLARE–TIMI 58 is the largest study to address this question with an SGLT-2 inhibitor in patients with T2DM and with established CV disease and without CV disease but with multiple risk factors.
Source: American Heart Journal - May 8, 2018 Category: Cardiology Source Type: research
Randomized placebo controlled trial evaluating the safety and efficacy of single low-dose intracoronary insulin-like growth factor following percutaneous coronary intervention in acute myocardial infarction (RESUS-AMI)
Conclusions In this pilot trial, low-dose IGF1, given after optimal mechanical reperfusion in STEMI, is safe but does not improve LVEF. However, there is a signal for a dose-dependent benefit on post-MI remodeling that may warrant further study.
Source: American Heart Journal - May 8, 2018 Category: Cardiology Source Type: research
Revival of transcatheter PFO closure: A meta-analysis of randomized controlled trials - impact of shunt size and age
Conclusion According to our meta-analysis TPC plus antiplatelets was superior in terms of stroke prevention when compared to Med-Tx. Furthermore, patients with moderate to severe shunts and those younger than 45 years of age were found to benefit most from TPC.
Source: American Heart Journal - May 26, 2018 Category: Cardiology Source Type: research
Harmony Outcomes: A randomized, double blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus —rationale, design, and baseline characteristics
Conclusions Harmony Outcomes will assess the CV safety of albiglutide in patients with T2DM and CV disease. Trials of other agents in the GLP-1 RA class have shown CV benefit for only some of these medications, possibly due to differences in trial design or instead due to differences in drug structure or metabolism. Harmony Outcomes will provide information critical to our understanding of this heterogenous class of glucose-lowering agents.
Source: American Heart Journal - June 13, 2018 Category: Cardiology Source Type: research
GlycA and hsCRP are independent and additive predictors of future cardiovascular events among patients undergoing angiography: The intermountain heart collaborative study
ConclusionIn this study, levels of GlycA and hsCRP were independent and additive markers of risk for MACE, death and HF hospitalization.
Source: American Heart Journal - July 5, 2018 Category: Cardiology Source Type: research
Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients–Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial
ConclusionCAMELLIA-TIMI 61 is investigating the safety and efficacy of lorcaserin for MACEs and conversion to diabetes in overweight or obese patients with established cardiovascular disease or multiple cardiovascular risk factors.
Source: American Heart Journal - July 5, 2018 Category: Cardiology Source Type: research
Harmony Outcomes: A randomized, double blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—rationale, design, and baseline characteristics
ConclusionsHarmony Outcomes will assess the CV safety of albiglutide in patients with T2DM and CV disease. Trials of other agents in the GLP-1 RA class have shown CV benefit for only some of these medications, possibly due to differences in trial design or instead due to differences in drug structure or metabolism. Harmony Outcomes will provide information critical to our understanding of this heterogenous class of glucose-lowering agents.
Source: American Heart Journal - July 5, 2018 Category: Cardiology Source Type: research
Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—Rationale, design, and baseline characteristics
ConclusionsHarmony Outcomes will assess the CV safety of albiglutide in patients with T2DM and CV disease. Trials of other agents in the glucagon-like peptide-1 receptor agonist class have shown CV benefit for only some of these medications, possibly due to differences in trial design or instead due to differences in drug structure or metabolism. Harmony Outcomes will provide information critical to our understanding of this heterogenous class of glucose-lowering agents.
Source: American Heart Journal - July 10, 2018 Category: Cardiology Source Type: research
